Our meta analyses and systematic review focus on one of the highly potent HDAC inhibitors called panobinostat which has been demonstrated that can affect the growth and survival of MM cells through alteration of epigenetic mechanisms and protein metabolism10, 11 and it has been found to be effective in patients with relapsed/refractory MM with an acceptable toxicity profile. Here, HDAC9 is linked to Miyoshi myopathy.